Literature DB >> 11557065

Ionizing radiation can overcome resistance to TRAIL in TRAIL-resistant cancer cells.

M R Kim1, J Y Lee, M T Park, Y J Chun, Y J Jang, C M Kang, H S Kim, C K Cho, Y S Lee, H Y Jeong, S J Lee.   

Abstract

Although the majority of cancer cells are killed by TRAIL (tumor necrosis factor-related apoptosis-inducing ligand treatment), certain types show resistance to it. Ionizing radiation also induces cell death in cancer cells and may share common intracellular pathways with TRAIL leading to apoptosis. In the present study, we examined whether ionizing radiation could overcome TRAIL resistance in the variant Jurkat clones. We first selected TRAIL-resistant or -sensitive Jurkat clones and examined cross-responsiveness of the clones between TRAIL and radiation. Treatment with gamma-radiation induced significant apoptosis in all the clones, indicating that there seemed to be no cross-resistance between TRAIL and radiation. Combined treatment of radiation with TRAIL synergistically enhanced killing of TRAIL-resistant cells, compared to TRAIL or radiation alone. Apoptosis induced by combined treatment of TRAIL and radiation in TRAIL-resistant cells was associated with cleavage of caspase-8 and the proapoptotic Bid protein, resulting in the activation of caspase-9 and caspase-3. No changes in the expressions of TRAIL receptors (DR4 and DR5) and Bcl-2 or Bax were found after treatment. The caspase inhibitor z-VAD-fmk completely counteracted the synergistic cell killing induced by combined treatment of TRAIL and gamma-radiation. These results demonstrated that ionizing radiation in combination with TRAIL could overcome resistance to TRAIL in TRAIL-resistant cells through TRAIL receptor-independent synergistic activation of the cascades of the caspase-8 pathway, suggesting a potential clinical application of combination treatment of TRAIL and ionizing radiation to TRAIL-resistant cancer cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11557065     DOI: 10.1016/s0014-5793(01)02816-2

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  11 in total

1.  Recombinant adenoviruses expressing TRAIL demonstrate antitumor effects on non-small cell lung cancer (NSCLC).

Authors:  F Yang; P Shi; X Xi; S Yi; H Li; Q Sun; M Sun
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

2.  In vitro effects of topotecan and ionizing radiation on TRAIL/Apo2L-mediated apoptosis in malignant glioma.

Authors:  Emilio Ciusani; Danilo Croci; Maurizio Gelati; Chiara Calatozzolo; Francesca Sciacca; Luisa Fumagalli; Marco Balzarotti; Laura Fariselli; Amerigo Boiardi; Andrea Salmaggi
Journal:  J Neurooncol       Date:  2005-01       Impact factor: 4.130

3.  Combination treatment of TRAIL, DFMO and radiation for malignant glioma cells.

Authors:  George A Alexiou; Konstantinos I Tsamis; Evrysthenis Vartholomatos; Evangelia Peponi; Eftychia Tzima; Ifigeneia Tasiou; Efstathios Lykoudis; Pericles Tsekeris; Athanasios P Kyritsis
Journal:  J Neurooncol       Date:  2015-05-03       Impact factor: 4.130

4.  Slug regulates proliferation and invasiveness of esophageal adenocarcinoma cells in vitro and in vivo.

Authors:  Kejun Zhang; Shaoyan Zhang; Xuelong Jiao; Haibo Wang; Dianliang Zhang; Zhaojian Niu; Yi Shen; Liang Lv; Yanbing Zhou
Journal:  Med Oncol       Date:  2010-08-21       Impact factor: 3.064

5.  Suppressing effects of daily oral supplementation of beta-glucan extracted from Agaricus blazei Murill on spontaneous and peritoneal disseminated metastasis in mouse model.

Authors:  Hiroshi Kobayashi; Ryuji Yoshida; Yasufumi Kanada; Yoichi Fukuda; Tatsuo Yagyu; Kiyokazu Inagaki; Toshiharu Kondo; Noriyuki Kurita; Mika Suzuki; Naohiro Kanayama; Toshihiko Terao
Journal:  J Cancer Res Clin Oncol       Date:  2005-05-10       Impact factor: 4.553

6.  Suppression of NF-kappa B survival signaling by nitrosylcobalamin sensitizes neoplasms to the anti-tumor effects of Apo2L/TRAIL.

Authors:  Mamta Chawla-Sarkar; Joseph A Bauer; Joseph A Lupica; Bei H Morrison; Zhuo Tang; Rhonda K Oates; Alex Almasan; Joseph A DiDonato; Ernest C Borden; Daniel J Lindner
Journal:  J Biol Chem       Date:  2003-07-24       Impact factor: 5.157

7.  Targeting a novel N-terminal epitope of death receptor 5 triggers tumor cell death.

Authors:  Peng Zhang; Yong Zheng; Juan Shi; Yaxi Zhang; Shilian Liu; Yanxin Liu; Dexian Zheng
Journal:  J Biol Chem       Date:  2010-01-27       Impact factor: 5.157

8.  Parallel screening of FDA-approved antineoplastic drugs for identifying sensitizers of TRAIL-induced apoptosis in cancer cells.

Authors:  David J Taylor; Christine E Parsons; Haiyong Han; Arul Jayaraman; Kaushal Rege
Journal:  BMC Cancer       Date:  2011-11-01       Impact factor: 4.430

9.  Apoptosis induction in renal cell carcinoma by TRAIL and gamma-radiation is impaired by deficient caspase-9 cleavage.

Authors:  U Ramp; E Caliskan; C Mahotka; A Krieg; S Heikaus; H E Gabbert; C D Gerharz
Journal:  Br J Cancer       Date:  2003-06-02       Impact factor: 7.640

10.  Induction of apoptosis in experimental human B cell lymphomas by conditional TRAIL-expressing T cells.

Authors:  E Ucur; J Mattern; T Wenger; S Okouoyo; A Schroth; K-M Debatin; I Herr
Journal:  Br J Cancer       Date:  2003-12-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.